NBIX Neurocrine Biosciences, Inc.

38.84
-2.44  -5.89%
Previous Close 41.27
Open 41.27
Price To book 10.20
Market Cap 3.37B
Shares 86,871,000
Volume 1,083,543
Short Ratio 3.55
Av. Daily Volume 1,108,450

SEC filingsSee all SEC filings

  1. 8-K - Current report 17514604
  2. 8-K - Current report 162069158
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161968261
  4. 8-K - Current report 161967969
  5. 8-K - Current report 161929506

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due April 2017.
INGREZZA
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
INGREZZA
Tourette syndrome - adults
Phase 3 initiated by partner Abbvie in January 2016. Data due 4Q 2017.
Elagolix
Uterine Fibroids
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA Filing due 3Q 2017.
Elagolix
Endometriosis
PDUFA date under priority review April 11, 2017. Announced January 5, 2017 that the Advisory Committee Meeting originally scheduled for February 16, 2016 has been cancelled.
INGREZZA
Tardive dyskinesia

Latest News

  1. NBIX: Phase 2 Study of INGREZZA™ in Adults with Tourette Syndrome Fails to Hit Primary Endpoint
  2. After hours buzz: CSX, UAL, GIMO & more
  3. Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down
  4. Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients
  5. Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome
  6. Here Are Two Market Moving Biotech Catalysts To Watch This Week
  7. Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : January 11, 2017
  8. Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : January 10, 2017
  9. NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
  10. NBIX: AdComm Meeting for INGREZZA™ Cancelled by FDA
  11. What Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NBIX)?
  12. These 5 Biotech Stocks Could Be Big Takeover Targets in 2017
  13. Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer
  14. Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia
  15. Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia
  16. Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference
  17. 7 Key FDA Decisions and Catalysts Expected in January and February
  18. NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers
  19. Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down
  20. Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down

SEC Filings

  1. 8-K - Current report 17514604
  2. 8-K - Current report 162069158
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161968261
  4. 8-K - Current report 161967969
  5. 8-K - Current report 161929506
  6. 8-K - Current report 161900170
  7. S-8 - Securities to be offered to employees in employee benefit plans 161804363
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 161804224
  9. 8-K - Current report 161804010
  10. 8-K - Current report 161670746